LUNDBECK AUSTRALIA PTY LTD

1 Innovation Rd, North Ryde, New South Wales, Australia

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

No trial phase data available

Trial Status Distribution

No trial data available

Clinical Trials

No trial data available

Approvals

Approvals by Agency

TGA

Therapeutic Goods Administration

Approvals

Recent Approvals

ABILIFY ASIMTUFII aripiprazole (as monohydrate) 720 mg/2.4 mL prolonged release suspension for injection pre-filled syringe (410032)

TGA

2025-02-05

ABILIFY ASIMTUFII aripiprazole (as monohydrate) 960 mg/3.2 mL prolonged release suspension for injection pre-filled syringe (410039)

TGA

2025-02-05

ABILIFY ASIMTUFII aripiprazole (as monohydrate) 960 mg/3.2 mL prolonged release suspension for injection pre-filled syringe (410039)

TGA

2025-02-05

ABILIFY ASIMTUFII aripiprazole (as monohydrate) 720 mg/2.4 mL prolonged release suspension for injection pre-filled syringe (410032)

TGA

2025-02-05

VYEPTI eptinezumab 100 mg/mL concentrated injection single use vial (335256)

TGA

2021-06-16

VYEPTI eptinezumab 100 mg/mL concentrated injection single use vial (335256)

TGA

2021-06-16

ABILIFY MAINTENA aripiprazole (as monohydrate) 300 mg powder and solvent for prolonged release suspension for injection pre-filled syringe (297643)

TGA

2018-05-07

ABILIFY MAINTENA aripiprazole (as monohydrate) 400 mg powder and solvent for prolonged release suspension for injection pre-filled syringe (297644)

TGA

2018-05-07

ABILIFY MAINTENA aripiprazole (as monohydrate) 300 mg powder and solvent for prolonged release suspension for injection pre-filled syringe (297643)

TGA

2018-05-07

ABILIFY MAINTENA aripiprazole (as monohydrate) 400 mg powder and solvent for prolonged release suspension for injection pre-filled syringe (297644)

TGA

2018-05-07

News

No news articles found

Back to Organizations